Henri Caplain
YOU?
Author Swipe
View article: Model‐Informed Drug Development of a Sustained Release Formulation of Flucytosine in the Treatment of Cryptococcal Meningitis: A Case Study Using Physiologically Based Pharmacokinetic Modeling
Model‐Informed Drug Development of a Sustained Release Formulation of Flucytosine in the Treatment of Cryptococcal Meningitis: A Case Study Using Physiologically Based Pharmacokinetic Modeling Open
This paper presents a case study demonstrating the application of model‐informed drug development (MIDD) and early modeling integration in the development of a sustained release (SR) formulation of flucytosine for cryptococcal meningoencep…
View article: Bioavailability of a novel sustained‐release pellet formulation of 5‐flucytosine in healthy‐fed participants for use in patients with cryptococcal meningitis
Bioavailability of a novel sustained‐release pellet formulation of 5‐flucytosine in healthy‐fed participants for use in patients with cryptococcal meningitis Open
Cryptococcal meningoencephalitis (CM) is an opportunistic fungal infection and a major cause of death among people living with human immunodeficiency virus in sub‐Saharan Africa. 5‐flucytosine (5‐FC) is a unique, brain‐permeable antifungal…
View article: Bioavailability of three novel oral, sustained‐release pellets, relative to an immediate‐release tablet containing 500 mg flucytosine: A randomized, open‐label, crossover study in healthy volunteers
Bioavailability of three novel oral, sustained‐release pellets, relative to an immediate‐release tablet containing 500 mg flucytosine: A randomized, open‐label, crossover study in healthy volunteers Open
The opportunistic fungal infection cryptococcal meningoencephalitis is a major cause of death among people living with HIV in sub‐Saharan Africa. We report pharmacokinetic (PK) and safety data from a randomized, four‐period crossover phase…
View article: PA-298 Predicting disease effect on the pharmacokinetics (PK) of sustained and immediate release formulations by applying physiologically based pharmacokinetic (PBPK) modelling
PA-298 Predicting disease effect on the pharmacokinetics (PK) of sustained and immediate release formulations by applying physiologically based pharmacokinetic (PBPK) modelling Open
Background 5-flucytosine (5FC) is used for the treatment of cryptococcal meningoencephalitis (CM) in patients with advanced HIV. The current dosing is four times a day involving high risks of low adherence and not adapted for severely ill …
View article: European Federation for Exploratory Medicines Development Lyon Conference 2019: The Changing Landscape of Early Medicines Development—Be Prepared
European Federation for Exploratory Medicines Development Lyon Conference 2019: The Changing Landscape of Early Medicines Development—Be Prepared Open
The second biennial conference of the European Federation for Exploratory Medicines Development (EUFEMED) was the result of a continued effort of EUFEMED to gather all stakeholders of exploratory clinical drug development to evaluate and d…
View article: EUFEMED London Conference 2017: Exploratory Medicines Development: Innovation and Risk Management
EUFEMED London Conference 2017: Exploratory Medicines Development: Innovation and Risk Management Open
The first formal conference of the EUropean Federation for Exploratory MEdicines Development (EUFEMED) held in London was the result of a collaborative effort of its founding associations: the Association for Applied Human Pharmacology (AG…